GeoVax Labs (NASDAQ:GOVX) Given “Buy” Rating at D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research note issued on Friday,Benzinga reports. They presently have a $18.00 price objective on the stock.

A number of other equities analysts have also recently weighed in on GOVX. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th. Alliance Global Partners assumed coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Price Performance

Shares of GOVX opened at $1.95 on Friday. The business’s 50-day moving average price is $2.35 and its 200 day moving average price is $2.74. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same period in the prior year, the business posted ($4.80) EPS. On average, equities research analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs as of its most recent SEC filing. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.